lavengratinib   Click here for help

GtoPdb Ligand ID: 14617

Synonyms: Example No. 15 [US12351576]
Compound class: Synthetic organic
Comment: Lavengratinib is the INN for a fibroblast growth factor receptor FGFR) inhibitor with antineoplastic potential that was included in WHO INN Proposed List 135 (July 2026). It is one of the compounds claimed in Abbisko Therapeutics' patent US12351576B2 [2]. The patent suggests that its compounds particularly inhibit the enzymatic activity of FGFR2 and/or FGFR3 kinases. Abbisko Therapeutics have a declared FGFR2/3 inhibitor in development, named ABSK061 [1], that could be a candidate for the INN.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 79.2
Molecular weight 544.43
XLogP 1.57
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1C2=CC(=NC=C2C=C(C3=C(C(=CC(=C3Cl)OC)OC)Cl)C1=O)C4=CN(CCN5CCOCC5)N=C4
Isomeric SMILES ClC1=C(C(=C(C=C1OC)OC)Cl)C=2C(N(C3=CC(=NC=C3C2)C=4C=NN(C4)CCN5CCOCC5)C)=O
InChI InChI=1S/C26H27Cl2N5O4/c1-31-20-11-19(17-14-30-33(15-17)5-4-32-6-8-37-9-7-32)29-13-16(20)10-18(26(31)34)23-24(27)21(35-2)12-22(36-3)25(23)28/h10-15H,4-9H2,1-3H3
InChI Key SQMXIBXIVSOOII-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
ABSK061 was progressed as an anti-tumour agent with potential to treat solid tumors with FGFR2/3 alterations. It may also have application in the treatment of achondroplasia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07297875 A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia Phase 1/Phase 2 Interventional Abbisko Therapeutics Co, Ltd
NCT06632262 A Phase 2 Clinical Study of ABSK061 and ABSK043 Phase 2 Interventional Abbisko Therapeutics Co, Ltd